9 citations
,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
3 citations
,
January 2008 in “Drug Safety” 14 citations
,
January 2025 in “Journal of Dermatological Treatment” Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
6 citations
,
November 2017 in “Dermatologic Therapy” Combining mometasone furoate cream with adapalene gel is safer and more effective for hair regrowth in alopecia areata than using the cream alone.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
1 citations
,
May 2017 in “Journal of Clinical Oncology” Topical calcitriol is safe for preventing hair loss during chemotherapy.
21 citations
,
March 2003 in “Acta Dermato Venereologica” Tacalcitol ointment effectively improves bilateral nevus comedonicus.
March 2023 in “Brazilian Journal of Health Review” The combination tablet of finasteride and doxazosin works the same as taking each drug separately.
September 2016 in “한국임상약학회지” Ibuprofen, menthol, and cetirizine may help prevent or slow hair loss.
36 citations
,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
8 citations
,
July 2011 in “Critical reviews in analytical chemistry” The document concludes that validated methods are needed to ensure the quality of fluconazole drugs and that new antifungal medications are necessary due to safety and resistance concerns.
1 citations
,
May 2021 in “Scientific Reports” Certain cancer drugs are strongly linked to nerve damage, requiring close monitoring and early treatment.
2 citations
,
February 2023 in “Actas Dermo-Sifiliográficas” Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
January 2024 in “Indonesian Journal of Pharmaceutical Education” The Caffein Herbasome® cream is stable and suitable for skin use.
13 citations
,
June 2010 in “Journal of dermatological treatment” Diphencyprone is effective for treating patchy hair loss in alopecia areata, but tacrolimus is not.
39 citations
,
January 1977 in “Dermatology” The treatment cleared psoriasis in some patients but caused side effects in most.
66 citations
,
June 2021 in “Journal of The American Academy of Dermatology” Baricitinib is effective and safe for treating severe alopecia areata.
97 citations
,
January 2006 in “Dermatology” imTA and pulse therapy are effective for alopecia areata with manageable side effects, but relapse rates need improvement.
November 2023 in “Children” Many pediatric epilepsy patients experience preventable severe adverse drug reactions, especially with certain medications and risk factors.
May 2024 in “Reactions weekly”
7 citations
,
July 2019 in “The Journal of Dermatology” Terbinafine effectively treated kerion celsi despite disrupted immune responses.
January 2008 in “xPharm: The Comprehensive Pharmacology Reference” 9 citations
,
November 2022 in “Journal of Cosmetic Dermatology” Combining cryotherapy with steroids reduces keloid size more effectively than steroids alone.
3 citations
,
January 2025 in “Journal of Natural Products” Calancardin B may help reduce inflammation in immune cells.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
8 citations
,
November 2022 in “Cureus” Lulican™ shampoo is more effective and better tolerated than Ketoconazole for treating scalp seborrheic dermatitis.
January 2024 in “Dermatologic Therapy” Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.
2 citations
,
May 2021 in “Research Square (Research Square)” Ketoconazole loaded solid lipid nanoparticles can penetrate skin better than regular drug suspension and marketed product, providing slow, sustained release and improved stability.
July 2024 in “Journal of Investigative Dermatology” DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.